Making the pain of injections go away in children, adults and seniors, is Israel's Sindolor. Based in Ramat Gan, under the TASE-traded mother company D Medical Industries, Sindolor is about to release its EZject drug delivery platform.
Missing: Sindolor's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Sindolor's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Sindolor Frequently Asked Questions (FAQ)
Who are Sindolor's competitors?
Competitors of Sindolor include Erydel, Sol-Gel, Medipacs, Intercell, Ekos and 9 more.
Compare Sindolor to Competitors
Medipacs develops a non-mechanical infusion pump using a expandable polymer. TheMedipacs pump is designed to be wearable, programmable and disposable to allow for greater accuracy, patient comfort and convenience at a lower cost. The Medipacs novel polymer technology enables drug infusion pumps that are wearable, programmable and disposable to allow for greater accuracy, patient comfort and convenience at a lower cost.
utilized "combinatorial chemistry" technology to discover lead therapeutic and diagnostic compounds.ï¿½MACUGEN, approved for wet age-related macular degeneration, was discovered using this technology. Upon NeXagen's merger with Vestar, Inc., the company also marketed and developed liposomal drug delivery products.
DendriMed, a spin-out from the University of Queensland, is developing a drug delivery platform that combines polymer and dendrimer nanotechnologies. The company is aiming to improve the delivery of a new class of drugs known as interfering RNA (RNAi) when applied to cancer treatment.
MAD Nanolayers aims to provide a patented coating technology for delivering multiple agents sequentially and with precise control over dosage and timing. This is a platform technology with many therapeutic and non-therapeutic applications and whose disruptive feature is not available in any other coating technology today. MAD Nanolayers' primary offering will be a therapeutic coating for orthopedic implants that aims to deliver painkillers, antibiotics, and growth factors to minimize post-surgical complications and aims to eliminate subsequent re-intervention procedures, resulting in cost-savings to the hospitals and improved quality of life for patients.
Cambridge Eyenovations is developing drug-eluting contact lenses that can dispense medicine automatically for glaucoma patients so that people don't need to put in eyedrops at all, and can go a month without changing contact lenses.
EZRA Innovations currently holds exclusive worldwide rights in a controlled-release drug delivery system. Drug Surfactant Complex (DSC) Deoxycholate is used in combination with active pharmaceutical ingredients (API), DSC possesses the ability to change the chemical moiety of existing drugs and better extend release rates.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.